|1.||Rossignol, Daniel P: 6 articles (05/2013 - 09/2004)|
|2.||Lynn, Melvyn: 6 articles (03/2013 - 09/2004)|
|3.||LaRosa, Steven P: 3 articles (03/2013 - 05/2011)|
|4.||Tidswell, Mark: 3 articles (03/2013 - 01/2010)|
|5.||Opal, Steven M: 3 articles (03/2013 - 01/2010)|
|6.||Wong, Nancy: 3 articles (12/2008 - 09/2004)|
|7.||Loughran, Patricia: 2 articles (01/2014 - 10/2013)|
|8.||Kalil, Andre C: 2 articles (03/2013 - 10/2011)|
|9.||Pearlman, Eric: 2 articles (01/2012 - 03/2009)|
|10.||Sun, Yan: 2 articles (01/2012 - 03/2009)|
01/01/2008 - "Evidence from a single phase II trial of eritoran usage in sepsis suggests that it is a safe and effective therapeutic option for patients with sepsis, and is especially beneficial for patients at high risk of mortality. "
07/01/2012 - "In January 2011, it was announced that the worldwide phase 3 randomized trial of a novel anti-Toll-like receptor-4 compound, eritoran tetrasodium, had failed to demonstrate an improvement in the mortality of patients with severe sepsis. "
01/01/2014 - "Although eritoran showed positive results in phase I and phase II clinical trials of severe sepsis, a phase III clinical study for severe sepsis has failed. "
10/01/2011 - "This analysis aimed to assess the efficacy of eritoran based on severity of illness and similar effects in other recent sepsis trials. "
03/20/2013 - "Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial."
06/01/2010 - "Protective effects of Toll-like receptor 4 inhibitor eritoran on renal ischemia-reperfusion injury."
07/04/2006 - "Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury."
01/01/2014 - "Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling."
05/23/2013 - "The TLR4 antagonist Eritoran protects mice from lethal influenza infection."
03/01/2012 - "In particular, eritoran is a synthetic tetraacylated lipid A that binds directly to MD-2 and antagonizes LPS binding to the same site, and it ameliorates various inflammatory conditions due to infection or sterile organ injury. "
05/23/2013 - "Thus, Eritoran blockade of TLR signalling represents a novel therapeutic approach for inflammation associated with influenza, and possibly other infections."
|4.||Wounds and Injuries (Trauma)
|5.||Multiple Organ Failure (MODS)
|2.||Toll-Like Receptor 4
|3.||Anti-Inflammatory Agents (Anti-Inflammatories)
|5.||drotrecogin alfa activated (Xigris)
|6.||salicylhydroxamic acid (SHAM)
|8.||Toll-Like Receptors (Toll-Like Receptor)
|9.||HMGB1 Protein (HMG1)
|10.||Brain Natriuretic Peptide (Natrecor)